A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
Open Access
- 17 August 2010
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (7) , 993-1000
- https://doi.org/10.1038/sj.bjc.6605852
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 32 references indexed in Scilit:
- Hypertension and proteinuria: a class-effect of antiangiogenic therapiesAnti-Cancer Drugs, 2009
- Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing StrategiesThe Oncologist, 2008
- Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patientsBritish Journal of Cancer, 2008
- Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogeneticsCancer, 2008
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard TherapyJournal of Clinical Oncology, 2007
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007
- A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancerAnnals of Oncology, 2005
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000